Ocugen Inc (NASDAQ: OCGN) is pleased to unveil the positive outcomes of a recent Covid-19 Vaccine trial. The study focused on children aged 2-18 years. The substance under study is COVAXIN™ (BBV152), and its outcomes inspire hope among the affected persons.
Progressive partnership
The company speaks out on its partner Bharat Biotech International Limited and its great work in coming up with COVAXIN™. A clinical investigation of the substance continues in the United States, and the target is to determine whether it could work for adults aged 18 years and above.
Siddharth Reddy, Dr. Krishna Mohan Vadrevu, and others developed the Lancet article. It is named Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine. Ocugen continues making all the critical moves, including taking over commercial rights for COVAXIN™ in North America.
The company has achieved tremendous success considering that COVAXIN™ qualifies for an emergency use authorization. However, the target users live in Mexico, mainly adults. Therefore, Ocugen has a lot to accomplish in the future. One of the things is to find ways to win over the emergency use authorization in Mexico to treat adult patients.
The data from the study demonstrate the appropriateness of the dose in both pediatrics and adults. In addition, most Americans seem more inclined to the traditional vaccine options, which means that the new product will find a massive market in the U.S. Ocugen continues to channel its vaccine to the North American Market.
Leaders share their perspectives
The Co-Founder of Ocugen, Dr. Shankar Musunuri, applauds Bharat Biotech for its successful publication of the COVAXIN™ pediatric data. He also describes the peer-reviewed medical journal as a rather prestigious and that it represents the great image of the company. Furthermore, he considers the move a great validation of the great efforts they continue to progress in developing a working solution.
He admits that the pandemic is a serious challenge and opines that it requires a great diversity of vaccine options to combat the various variants.
The Managing Director of Bharat Biotech, Dr. Krishna Ella, considers Ocugen a worthy partner. He believes their joint efforts will enable them to succeed in moving COVAXIN™ to North America.
